Loading Events

Upcoming Events

Events Search and Views Navigation

Event Views Navigation

September 2021

HANDS Animal Model Webinar Series – Week 2: Adult Animal Models

September 24 @ 12:00 pm - November 22 @ 1:15 am

Date: Friday, September 24th
Time: 12:00 to 1:15 PM EDT

Speakers:

  • Sravanthi Koduri (University of Michigan) – Injection of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhages (aSAH) into mouse ventricles for hydrocephalus induction
  • Simon Shim (Marshall University) – Rat model with a TMEM67 heterozygous mutation demonstrating hemorrhage at birth and developing late-onset hydrocephalus in adults
  • Margaret Tish (University of Iowa) – Induction of chronic, communicating hydrocephalus in adult mice using kaolin

Register here!

Find out more »

October 2021

HANDS Animal Model Webinar Series – Week 4: Congenital Genetic Animal Models

October 22 @ 12:00 pm - 1:15 pm

Date: Friday, October 22nd
Time: 12:00 to 1:15 PM EDT

Speakers:

  • Ryan Gray (University of Texas at Austin) – K1F6 mutant mice models demonstrating progressive loss of ependymal cell cilia and hydrocephalus development
  • Bernadette Holdener (Stony Brook University) – B3glct mutant mice models demonstrating development of hydrocephalus and ventriculomegaly

Register Here!

Find out more »

HANDS Animal Model Webinar Series – Week 5: Posthemorrhagic Animal Models

October 29 @ 12:00 pm - 1:15 pm

Date: Friday, October 29th
Time: 12:00 to 1:15 PM EDT

Speakers:

  • Lauren Jantzie & Dody Robinson (Johns Hopkins Medicine) – Rat model of hydrocephalus via induction of chorioamnionitis (in utero inflammation) and ICV injection of lysed littermate red blood cells postnatally
  • Jennifer Strahle (Washington University School of Medicine in St. Louis) – Mouse model of posthemorrhagic hydrocephalus using the injection of blood products

Register Here!

Find out more »

November 2021

Clinical Scientist Development Award

November 12

Sponsor: Doris Duke Charitable Foundation
Eligibility Exemption Requests Due: October 15, 2021 at 5 pm ET
Pre-Proposal Applications Due: November 12, 2021 at 3 pm ET
Award: $150,000 annual direct costs plus $15,000 (10%) annual indirect costs for three years

Find out more »

December 2021

Cycle 1: Alzheimer’s Drug Discovery Foundation

December 3
|Recurring Event (See all)

One event on December 3, 2021 at 12:00 am

LOI Due Dates:

  • Cycle 1: May 28, 2021
  • Cycle 2: October 1, 2021

Full Proposal Deadlines:

  • Cycle 1: July 30, 2021
  • Cycle 2: December 3, 2021

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

December 31

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years. Grant awards must be comprised of very specific programs that are focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates.

Find out more »

Rolling Basis: Alzheimer’s Drug Discovery Foundation

December 31

PROPOSALS ACCEPTED ON A ROLLING BASIS
ADDF/NIH
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Conference Funding
Supports scientific conferences that are relevant to our mission with grants up to $10,000.

Find out more »

February 2022

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

February 9, 2022
|Recurring Event (See all)

One event on February 9, 2022 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Dates: 30 days before deadline
Due Date: August 10, 2021, February 9, 2022
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »
+ Export Events